Evaluation of donepezil in Alzheimer's disease - Experience from an Australian memory clinic

被引:0
|
作者
Mador, Julie [1 ]
Hecker, Jane [1 ]
Clark, Michael [1 ]
机构
[1] Flinders Univ S Australia, Repatriat Gen Hosp, Dept Rehabil & Aged Care, Daw Pk, Australia
关键词
D O I
10.1111/j.1741-6612.2003.tb00486.x
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Objectives: To describe our experience using cholinesterase inhibitors for mild-moderate Alzheimer's disease in a memory clinic. In particular we reviewed response in cognition, activities of daily living and quality of life for patients. Design: A prospective descriptive study with patients and carers being assessed before and 3-6 months after commencing treatment with a cholinesterase inhibitor. Setting: Memory clinic at Repatriation General Hospital, Adelaide. Subjects: Sixty-four consecutive patients with mild-moderate Alzheimer's disease commencing treatment with a cholinesterase inhibitor and their carers. Outcome Measures: The primary outcome was a change in cognition as measured 6y the Mini-Mental Status Examnination (MMSE). Secondary outcomes were The Alzheimer's Disease Functional Assessment and Change Scale (ADFACS), patient self-assessed measures of quality of life (Dementia Quality of Life Instrument (DQOL) with sub-scales in self-esteem, positive affect, negative affect, belonging and aesthetics, and a five point likert scale of overall quality of life (QOL)) and carer assessed proxy direct scaling of patient quality of life. Results: All patients were commenced on Donepezil. Fifty-four (84%) patients remained on drug treatment and completed the study with follow-up at an average of 13 weeks. Ten patients (16%) stopped treatment due to side-effects or non-compliance. There was a mean change of 1.1 points on the MMSE (p < 0.05) and a small but significant (p < 0.05) improvement in the positive affect sub-scale of the DQOL. There were no improvements in other sub-scales of the DQOL or overall quality of life. A similar number of patients improved 14 (26%) in activities of daily living as those who deteriorated 12 (22%) with the majority 28 (52%) remaining unchanged. Conclusion: Donepezil has a beneficial effect on cognition and affect when used in the setting of a memory clinic. There was little evidence to suggest an improvement in activities of daily living and overall quality of life.
引用
收藏
页码:146 / 150
页数:5
相关论文
共 50 条
  • [1] Donepezil in Alzheimer's disease: Eighteen month results from Southampton Memory Clinic
    Matthews, HP
    Korbey, J
    Wilkinson, DG
    Rowden, J
    INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2000, 15 (08) : 713 - 720
  • [2] Evaluation of the needs of caregivers for patients with Alzheimer's disease: experience in a memory clinic
    Nobili, G.
    Masaia, M.
    Isaia, G.
    Capa, G.
    Pilon, S.
    Mondino, S.
    Bo, M.
    Isaia, G. C.
    GIORNALE DI GERONTOLOGIA, 2011, 59 (02) : 71 - 74
  • [3] The effect of Donepezil on memory and attention tests in Alzheimer's disease
    Ivanoiu, A
    Vanderlinden, M
    Seron, X
    Maloteaux, JM
    Sindic, CJM
    NEUROLOGY, 1999, 52 (06) : A482 - A483
  • [4] An economic evaluation of donepezil in the treatment of Alzheimer's disease
    Small, GW
    Donohue, JA
    Brooks, RL
    CLINICAL THERAPEUTICS, 1998, 20 (04) : 838 - 850
  • [5] Biomarkers of Alzheimer's disease in mild cognitive impairment: Experience in a memory clinic from Latin America
    Allegri, R. F.
    Mendez, P. Chrem
    Russo, M. J.
    Cohen, G.
    Calandri, I
    Campos, J.
    Nahas, F.
    Surace, E.
    Vazquez, S.
    Sevlever, G.
    NEUROLOGIA, 2021, 36 (03): : 201 - 208
  • [6] Donepezil for Alzheimer's disease
    Sparano, N
    JOURNAL OF FAMILY PRACTICE, 1998, 46 (05): : 356 - 356
  • [7] Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada
    O'Brien, BJ
    Goeree, R
    Hux, M
    Iskedjian, M
    Blackhouse, G
    Gagnon, M
    Gauthier, S
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 1999, 47 (05) : 570 - 578
  • [8] Economic evaluation of donepezil for treatment of Alzheimer's disease in Canada
    O'Brien, B
    Goeree, R
    Hux, M
    Iskedjian, M
    Blackhouse, G
    Gauthier, S
    Gagnon, M
    MEDICAL DECISION MAKING, 1998, 18 (04) : 482 - 482
  • [9] Economic evaluation of donepezil treatment for Alzheimer's disease in Japan
    Ikeda, S
    Yamada, Y
    Ikegami, N
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2002, 13 (01) : 33 - 39
  • [10] Pharmacokinetic and pharmacodynamic evaluation of donepezil for the treatment of Alzheimer's disease
    Prvulovic, David
    Schneider, Barbara
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2014, 10 (07) : 1039 - 1050